ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 147 filers reported holding ASCENDIS PHARMA A/S in Q4 2019. The put-call ratio across all filers is 0.23 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $12,000 | -20.0% | 127 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $15,000 | -6.2% | 127 | -7.3% | 0.00% | 0.0% |
| Q1 2019 | $16,000 | +14.3% | 137 | -39.1% | 0.00% | 0.0% |
| Q4 2018 | $14,000 | -62.2% | 225 | -57.1% | 0.00% | 0.0% |
| Q3 2018 | $37,000 | 0.0% | 524 | -6.3% | 0.00% | 0.0% |
| Q2 2018 | $37,000 | +311.1% | 559 | +299.3% | 0.00% | – |
| Q1 2018 | $9,000 | – | 140 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |